• 名称: NCCIT人畸胎瘤细胞
  • 货号: CBP61089
  • 浏览次数: 119
  • 已销售数量:0件
  • 评论信息
  • 购买数量:  购买数量不能低于最少订购数量!

购买 询价 收藏 QQ交流 好友推荐

CBP61089
I. General information 
Synonyms: NCCIT
Background: NCCIT was established by Shinichi Teshima (National Cancer Institute, Tokyo, Japan) in 1985 from a mediastinal mixed germ cell tumor.
Species: Homo sapiens, human
Tissue: anterior mediastinal mixed germ cell tumor
Disease: pluripotent embryonal carcinoma; teratocarcinoma
Gender: male, adult, Japanese
Morphology: epithelial
Growth Mode: adherent
Doubling Time: N/A
DNA Profile: Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 9,12
D5S818: 10,13
D7S820: 10
THO1: 7,9
TPOX: 8
vWA: 14,18
Cobioer’s Cell Line Authentication Service
Culture Medium: RPMI 1640+10% FBS
We strongly suggest to purchase the complete medium from Cobioer.
Cryopreservation medium: 90%FBS+10%DMSO
Antigen Expression: N/A
Receptor Expression: N/A
Oncogene: N/A
Genes Expressed: N/A
Cellular Products: N/A
Tumor Formation: Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 107 cells.
Comments:  
This pluripotent stem cell line is capable of somatic and extraembryonic differentiation.
The undifferentiated cells are equivalent to a stage intermediate between seminoma and embryonal carcinoma.
They will differentiate in response to retinoic acid.
NCCIT cells are negative for keratin.
They are positive for vimentin and placental alkaline phosphatase.
The line was contaminated with mycoplasma, but was cured by the depositor prior to deposit at the ATCC.
For more information, please contact Cobioer (4008-750-250).

关键词: